Neupulse

Neupulse

Private
NottinghamHealthcare & Life Scienceshttps://neupulse.co

Last Round

Early Funding

Feb 13, 2026

Total Funding Raised

$7.65M

Momentum Score

25 /100

Company Overview

Neupulse is a healthtech company that develops a wearable neuromodulation device designed to reduce tics for individuals with Tourette's Syndrome.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Health IoT, Mental Health, Patient Engagement

Business Model

B2B

Customer Profile

Hardware + Subscription, Hardware Sales, Government Contracts

AI Layer

Non-AI

Keywords

neuromodulationTourette Syndromewearable medical devicetic reductionneurostimulatormedian nerve stimulationelectrical stimulationnon-invasive treatmentdrug-free therapyneurotechnologychronic tic disorderwrist-worn deviceDTC medical devicehardware and subscriptioncompanion mobile app

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Neupulse Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Neupulse Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Early FundingFeb 13, 2026
SeedJul 31, 2024
SeedMar 18, 2024

Key People

Founding team and executive leadership

Paul Cable

Chief Executive Officer

Executive Team

David Moser

Chief Technology Officer

Executive Team

Neupulse Investors

Notable investors and investment history

InvestorRounds
Mercia VenturesEarly Funding, Seed
Midlands Engine Investment Fund IISeed, Early Funding
Eos AdvisoryEarly Funding, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 13, 2026

    $3.8M raised in early funding.

  • Jan 4, 2026

    Preparing for EU MDR and FDA submissions for market entry.

Neupulse Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Neupulse Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Neupulse's valuation, stock price, and market status.

Firmographic Details

HeadquartersNottingham
Employee Range13
Year Founded2021
Last FundingFeb 13, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.